Artificial Pancreas Device Systems consists of two types of devices for diabetes monitoring: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) used to calibrate the CGM. These devices are intended to reduce hypoglycemic excursions by automatically suspending insulin administration for up to two hours when an individual’s glucose level drops below a preset level, if the individual does not respond to the threshold-suspend alarm. In 2016, the MiniMed 670G System (Medtronic), a hybrid-closed loop insulin delivery system, received FDA approval. This device is the first fully automated artificial pancreas device system. It consists of an insulin pump, a glucose meter, and a transmitter, linked by a proprietary algorithm, and the SmartGuard Hybrid Closed Loop. The system can be programmed to suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values and automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values.
Increasing prevalence of diabetes is anticipated to promote the demand for Artificial Pancreas Device Systems. Intensive R&D efforts by industry players and rising demand for automated systems for glycemic control are the other factors driving the market growth
The report segments the Artificial Pancreas Device Systems market based on product as, Threshold suspended device system, CTR system, and CTT system.
This report is a comprehensive study of current trends in the market, industry growth drivers, and restraints. These markets are given analysis at regional level to provide exhaustive value market analysis for the years 2016, 2017, 2018, and forecast to 2023. Each market is comprehensively analyzed at a granular level by region (North America, Europe, Asia-Pacific, and RoW) to provide in-depth information on the global scenario.
The key players in the global artificial pancreas device systems market are Medtronic; Bigfoot Biomedical; Johnson & Johnson; Tandem Diabetes Care, Inc.; Pancreum, Inc.; and TypeZero Technologies, LLC among others.
Table of Contents
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.6 Market Stakeholders
2 Research Methodology
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Key Data From Secondary Sources
2.4 Key Data From Primary Sources
2.5 Assumptions for the Study
3 Executive Summary
4 Premium Insights
5 Market Overview
5.2 Market Dynamics
6 Artificial Pancreas Device Systems Market, By Product
6.2 Threshold Suspended Device System
6.3 CTR System
6.4 CTT System
7 Artificial Pancreas Device Systems Market, By Region
7.2 North America
7.4 Asia Pacific
8 Competitive Landscape
8.2 Key Player Ranking Analysis (2017)
8.3 Competitive Scenario
8.3.1 Agreements, Partnerships, Collaborations, and Contracts
8.3.4 Product Launches
10 Company Profiles (Overview, Products and Services, Financials, Strategy & Development)
10.3 Bigfoot Biomedical
10.4 Johnson & Johnson
10.5 Tandem Diabetes Care, Inc.
10.6 Pancreum, Inc.
10.7 Typezero Technologies, LLC
10.8 Beta Bionics
10.9 Insulet Corp
10.10 F. Hoffmann-La Roche Ltd
10.11 Inreda Diabetic B.V.
The Segmentation Given May Change Depending on Research Findings.
The List of Companies May Change as Per Further Research Findings. Top 10 Companies Will Be Profiled in This Section. Details on Overview, Products, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies
Years Considered for the Study Would Be Historical Year – 2016, Base Year – 2017, Estimated Year – 2018, Forecast Period – 2018 to 2023
The Market Tables Would Include Value Data in USD for the Years 2016, 2017, 2018 and Forecasted Value for 2023 Along With CAGR for the Period 2018-2023
Benchmarking the rapid strategy shifts of the Top 100 companies in the Artificial Pancreas Device System (APDS) MarketRequest For Special Pricing